Skip to main content
SpringerLink
Log in

Pharmakotherapie schizophrener Störungen

  • Chapter
Psychiatrie der Gegenwart 5

Zusammenfassung

Seit vor nunmehr einem halben Jahrhundert erstmals eine wirksame Behandlung für Patienten mit schizophrenen Störungen entwickelt worden war, die einen revolutionären Fortschritt in der Therapie psychiatrischer Erkrankungen einleitete, ist diese neue Ära geprägt von der Bemühung, Behandlungserfolge zu optimieren. Eine Fülle von neuen Substanzen, in der klassischen psychopharmakologischen Terminologie als Neuroleptika bezeichnet — neuerdings wird immer mehr dem indikationsbezogenen Begriff Antipsychotika der Vorzug gegeben — wurde zu diesem Behufe synthetisiert und klinisch geprüft. Chemisch unterschiedlichst strukturierte Moleküle, die von den trizyklischen Phenothiazinen über Thioxanthene, Butyrophenone, Dibenzazepine, substituierte Benzamide bis hin zu einem Benzisoxazolderivat reichen, kommen heute bei dieser Indikation zum Einsatz.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Adler LA, Edson R, Lavori P, Peselow E, Duncan E, Rosenthal M, Rotrosen J (1998) Long-term treatment effects of vitamin E for tardive dyskinesia. Biol Psychiatry 43: 868–872

    CAS  Google Scholar 

  • Aitchison K, Kerwin RW (1997) Cost- effectiveness of clozapine. Br J Psychiatry 171: 125–130

    PubMed  CAS  Google Scholar 

  • Altamura CA, Colacurcio F, Mauri MC, Moro AR, DeNovellis F (1989) Haloperidol decanoate in chronic schizophrenia: a study of 12 months with plasma levels. Prog Neuropsychopharmacol Biol Psychiatry 14: 25–35

    Google Scholar 

  • Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA (1993) Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 329: 162–167

    PubMed  CAS  Google Scholar 

  • APA (1992) Tardive dyskinesia: a task force report of the American Psychiatric Association. American Psychiatric Press, Washington DC

    Google Scholar 

  • APA (1997) Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 54 (Suppl 4)

    Google Scholar 

  • Arato M, O’Connor R, Meitzer H, Bradbury J (1997) Ziprasidone: efficacy in the prevention of relapse and in the long-term treament of negative symptoms of chronic schizophrenia. Eur Neuropsychopharmacol 7 (Suppl 2)

    Google Scholar 

  • Arvanitis LA, Miller BG, Seroquel Trial 13 Study Group (1997) Multiple fixed doses of SeroqueP (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 42: 233–246

    Google Scholar 

  • Baldessarini RJ, Cohen BM, Teicher MH (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 4579–91

    Google Scholar 

  • Barnas C, Stuppäck C, Miller C, Haring C, Sperner-Unterweger B, Fleischhacker WW (1992) Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms: a double blind trial vs. haloperidol. Int Clin Psychopharmacol 7: 23–27

    PubMed  CAS  Google Scholar 

  • Bäuml J, Kissling W, Buttner P et al. (1993) Informationszentrierte Patienten- und Angehörigengruppen zur Complianceverbesserung bei schizophrenen Psychosen. Verhaltenstherapie 3 (Suppl 1): 1–96

    Google Scholar 

  • Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S (1996) Olanzapine versus placebo and haloperidol: acute phase results of the North-American double-blind olanzapine trial. Neuropsychopharmacology 14: 111–123

    PubMed  CAS  Google Scholar 

  • Bilder RM (1998) The neuropsychology of schizophrenia what, when, where, how? In: Fleischhacker WW, Hinterhuber H, Meise U (Hrsg) Schizophrene Störungen state of the art II. Verlag Integrative Psychiatrie, Innsbruck, S 155–171

    Google Scholar 

  • Bissette G, Nemeroff CB (1995) The neurobiology of neurotensin. In: Bloom FE, Kupfer DE (eds) Psychopharmacology: the fourth generation of progress. Raven, New York, pp 573–583

    Google Scholar 

  • Blackwell B (1973) Drug therapy: patient compliance. N Engl J Med 289: 249–252

    PubMed  CAS  Google Scholar 

  • Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, Baumann P (1998) Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperodone Study Group. Am J Psychiatry 155: 499–504

    PubMed  CAS  Google Scholar 

  • Borison RL, Arvanitis LA, Miller BG (1996) ICI 204.636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. Seroquel Study Group. J Clin Psychopharmacol 16:158– 169

    Google Scholar 

  • Boyer P, Lecrubier Y, Puech AJ, De- wailly J, Aubin F (1995) Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 166: 68–72

    PubMed  CAS  Google Scholar 

  • Buchanan A (1992) A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 22: 787–797

    PubMed  CAS  Google Scholar 

  • *Bunney BG, Bunney WE, Carlsson A (1995) Schizophrenia and glutamate. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress, Raven, New York, pp 1205–1214

    Google Scholar 

  • Byerly MJ, DeVane CL (1996) Pharmacokinetics of clozapine and risperidone: a review of recent literature. J Clin Psychopharmacol 16: 177–187

    PubMed  CAS  Google Scholar 

  • Bymaster FP, Calligaro DO, Falcone JF et al. (1996) Radioreceptor binding profile of the atypicalantipsychotic olanzapine. Neuropsychopharmacology 14: 87–96

    PubMed  CAS  Google Scholar 

  • Caldwell CB, Gottesman II (1990) Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr Bull 16: 571–589

    PubMed  CAS  Google Scholar 

  • Caligiuri MP, Lohr JB, Jeste DV (1993) Parkinsonism in neuroleptic-naive schizophrenic patients. Am J Psychiatry 150: 1343–1348

    PubMed  CAS  Google Scholar 

  • Carpenter WT Jr, Hanlon TE, Heinrichs DW, Summerfeit AT, Kirkpatrick B, Levine J, Buchanan RW (1990) Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 147: 1138–1148

    PubMed  Google Scholar 

  • Carpenter WT Jr (1996) The treatment of negative symptoms: pharmacological and methodological issues. Br J Psychiatry 168 (Suppl 29): 17–22

    Google Scholar 

  • Casey DE (1996) Extrapyramidal syndromes: Epidemiology, pathophysiology and the diagnostic dilemma. CNS Drugs 5 (Suppl 1): 1–12

    Google Scholar 

  • Chatterjee A, Chakos M, Koreen AR et al. (1995) Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 152: 1724–1729

    PubMed  CAS  Google Scholar 

  • Claghorn J, Honigfeld G, Abuzzahab FS, Wang R, Steinbook R, Tuason V, Klerman G (1987) The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 7: 377–384

    PubMed  CAS  Google Scholar 

  • Collaborative Working Group on Clinical Trial Evaluations (1998) Evaluating the effects of antipsychotics on cognition in schizophrenia. J Clin Psychiatry 59 (Suppl 12): 35–40

    Google Scholar 

  • Collins PJ, Larkin EP, Shubsachs APW (1991) Lithium carbonate in chronic schizophrenia a brief trial of lithium carbonate added to neuroleptics for treatment of resistant schizophrenic patients. Acta Psychiatr Scand 84: 150–154

    PubMed  CAS  Google Scholar 

  • Conley RR, Tamminga CA, Bartko JJ et al. (1998) Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 155: 914–920

    PubMed  CAS  Google Scholar 

  • Coryell W, Miller DD, Perry PJ (1998) Haloperidol plasma levels and dose optimization. Am J Psychiatry 155: 48–53

    PubMed  CAS  Google Scholar 

  • Coukell AJ, Spencer CM, Benfield P (1996) Amisulpride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 6: 237–256

    CAS  Google Scholar 

  • Crow TJ, McMillan JF, Johnson AL, Johnstone EC (1986) The Northwick Park study of first episodes of schizophrenia, II. A randomized controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 148: 120–127

    PubMed  CAS  Google Scholar 

  • Csernansky JG, Newcomer JG (1995) Maintenance drug treatment for schizophrenia. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress, Raven, New York, pp 1267–1275

    Google Scholar 

  • Daniel DG, Wozniak P, Mack RJ, McCarthy BG (1998) Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Psychopharmacol Bull 34: 61–69

    PubMed  CAS  Google Scholar 

  • Danion JM, Neunreuther C, Krieger- Finance F, Imbs JL, Singer L (1987) Compliance with long- term lithium treatment in major affective disorders. Pharmacopsychiatry 20: 230–231

    PubMed  CAS  Google Scholar 

  • Davis JM, Kane JM, Marder SR et al. (1993) Dose response of prophylactic antipsychotics. J Clin Psy-chiatry 54 (Suppl 3): 24–30

    Google Scholar 

  • Davis JM, Matalón L, Watanabe MD, Blake LM (1994) Depot antipsychotic drugs: place in therapy. Drugs 47741–773

    Google Scholar 

  • Davis R, Markham A (1997) Ziprasidone. CNS Drugs 8: 153–159

    CAS  Google Scholar 

  • Decina P, Mukherjee S, Bocola V, Saraceni F, Hadjichristos C, Scapicchio P (1994) Adjunctive trazodone in the treatment of negative symptoms of schizophrenia. Hosp Community Psychiatry 45:1220– 1223

    Google Scholar 

  • Deutch AY, Duman RS (1996) The ef-fects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: cellular localization and pharmacological characterization. Neuroscience 70: 377–389

    PubMed  CAS  Google Scholar 

  • Dieterle DM, Müller-Spahn F, Ackenheil M (1991) Effectiveness and tolerance of zotepine in a double- blind comparison with perazine in schizophrenic patients. Fortschr Neurol Psychiatr 59 (Suppl 1): 18–22

    PubMed  Google Scholar 

  • Drake RE, Osher FC, Wallach MA (1989) Alcohol use and abuse in schizophrenia. J Nerv Ment Dis 177: 408–414

    PubMed  CAS  Google Scholar 

  • Duinkerke SJ, Botter PA, Jansen AI et al. (1993) Ritanserin, a selective 5–HT2/IC antagonist, and negative symptoms in schizophrenia: a placebo-controlled double-blind trial. Br J Psychiatry 163: 451–455

    PubMed  CAS  Google Scholar 

  • Dunn CJ, Fitton A (1996) Sertindole. CNS Drugs 5: 224–230

    CAS  Google Scholar 

  • Eckman TA, Liberman RP, Phipps CC, Blair KE (1990) Teaching medication management skills to schizophrenic patients. J Clin Psychopharmacol 10: 33–38

    PubMed  CAS  Google Scholar 

  • Farde L, Nyberg S (1998) Dosing determination for novel antipsychotics - a PET-based approach. Int J Psychiatry Clin Pract 2 (Suppl 1): 39–42

    Google Scholar 

  • Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) PET analysis of central Di and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine - relation to extrapyramidal side effects. Arch Gen Psychiatry 49: 538–544

    PubMed  CAS  Google Scholar 

  • Fayen M, Goldman MB, Moulthrop MA, Luchins DJ (1988) Differential memory function with dopaminergic versus anticholinergic treatment of drug induced extrapyramidal symptoms. Am J Psychiatry 145: 483–486

    PubMed  CAS  Google Scholar 

  • Fenton WS, Blyler CR, Heinssen RK (1997) Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 23: 637–651

    PubMed  CAS  Google Scholar 

  • Fischer-Cornelssen KA, Ferner VJ (1976) An example of European multicenter trials: multispectral analysis of clozapine. Psychopharmacol Bull 12: 34–39

    PubMed  CAS  Google Scholar 

  • Fitton A, Heel R (1990) Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 40: 722–747

    PubMed  CAS  Google Scholar 

  • Fleischhacker WW (1998) Differentiation of depression, negative symptoms, and EPS in schizophrenia. J Clin Psychiatry(Monograph Series)16: 5–7

    Google Scholar 

  • Fleischhacker WW, Hummer M (1997) Drug treatment of schizophrenia in the 1990s: achievements and future possibilities in optimising outcomes. Drugs 53: 915–929

    PubMed  CAS  Google Scholar 

  • Fleischhacker WW, Barnas C, Günther V, Meise U, Stuppäck CH, Unterweger B (1987) Mood- altering effects of biperiden in healthy volunteers. J Affect Dis 12: 153–157

    PubMed  CAS  Google Scholar 

  • Fleischhacker WW, Barnas C, Stuppäck CH, Unterweger B, Miller CH, Hinterhuber H (1989) Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial. Psychopharmacol Bull 25: 97–100

    PubMed  CAS  Google Scholar 

  • Fleischhacker WW, Roth SD, Kane JM (1990) The pharmacologic treatment of neuroleptic-induced akathisia. J Clin Psychopharmacol 10: 12–21

    PubMed  CAS  Google Scholar 

  • Fleischhacker WW, Hummer M, Kurz M, Kurzthaler I, Lieberman J, Pollack S, Safferman A, Kane J (1994a) Clozapine dose in the US and Europe: implications for therapeutic and adverse effects. J Clin Psychiatry 55 (Suppl 9B): 78–81

    Google Scholar 

  • Fleischhacker WW, Meise U, Günther V, Kurz M (1994b) Compliance with antipsychotic drug treatment: influence of side-effects. Acta Psychiatr Scand 89 (Suppl 382): 11–15

    Google Scholar 

  • Fulton B, Goa KL (1995) ICI-204,636. An initial appraisal of its pharmacological properties and clinical potential in the treatment of schizophrenia. CNS Drugs 4: 68–78

    Google Scholar 

  • Fulton B, Goa KL (1997) Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 53: 281–298

    PubMed  CAS  Google Scholar 

  • Gaebel W, Falkai P (1998) Praxisleitlinien in Psychiatrie und Psychotherapie, Bd 1: Behandlungsleitlinie Schizophrenie, Steinkopff, Darmstadt

    Google Scholar 

  • Gardos G, Cole JO (1995) The treatment of tardive dyskinesia. In: Bloom F, Kupfer DJ (eds) Psycho- pharmacology: the fourth generation of progress, Raven, New York, pp 1503–1511

    Google Scholar 

  • Gardos G, Casey DE, Cole JO et al. (1994) Ten-year outcome of tardive dyskinesia. Am J Psychiatry 151: 836–841

    PubMed  CAS  Google Scholar 

  • Gerlach J, Koppelhus P, Helweg E, Monrad A (1974) Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand 50: 410–424

    PubMed  CAS  Google Scholar 

  • Gilbert PL, Harris MJ, McAdams LA, Jeste DV (1995) Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry 52: 173–188

    PubMed  CAS  Google Scholar 

  • Glazer WM, Johnstone BM (1997) Pharmacoeconomic evaluation of antipsychotic therapy for schizo-phrenia. J Clin Psychiatry 58 (Suppl 010): 50–54

    PubMed  Google Scholar 

  • Goff DC, Brotman AW, Waites M, McCormick S (1990) Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. Am J Psychiatry 147: 492–494

    PubMed  CAS  Google Scholar 

  • Goff DC, Midha KK, Sarid-Segal 0, Hubbard JW, Amico E (1995) A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology 117: 417–423

    PubMed  CAS  Google Scholar 

  • Goff DC, Posever T, Herz L et al. (1998) An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 18: 296–304

    PubMed  CAS  Google Scholar 

  • *Goldberg TE, Gold JM (1995) Neurocognitive deficits in schizophrenia. In: Hirsch SR, Weinberger DR (eds) Schizophrenia, Blackwell, Oxford, pp 146–162

    Google Scholar 

  • *Green M, Marshall BD Jr, Wirshing WC et al. (1997) Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 154: 799–804

    PubMed  CAS  Google Scholar 

  • Growe GA, Crayton JA, Klass DB (1979) Lithium in chronic schizophrenia. Am J Psychiatry 136:454– 455

    Google Scholar 

  • Hale A, Van der Burght M, Wehnert A, Friberg HH (1996) A European dose-range study comparing the efficacy, tolerability and safety of four doses of sertindole and one dose of haloperidol in schizophrenic patients. (Poster presented at the XXth CINP Congress, Melbourne, June 23–27 1996 )

    Google Scholar 

  • Hamilton SH, Revicki DA, Genduso LA, Beasley CM Jr (1998) Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsycho-pharmacology 18: 41–49

    CAS  Google Scholar 

  • Haring C, Fleischhacker WW, Schett P, Humpel C, Barnas C, Saria A (1990) Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry 147: 1471–1475

    PubMed  CAS  Google Scholar 

  • Haring C, Neudorfer C, Schwitzer J, Hummer M, Saria A, Hinterhuber H, Fleischhacker WW (1994) EEG alterations in patients treated with clozapine in relation to plasma levels. Psychopharmacology 114: 97–100

    PubMed  CAS  Google Scholar 

  • Herz MI, Glazer WM, Mostert MA et al. (1991) Intermittent vs maintenance medication in schizophrenia: two-year results. Arch Gen Psychiatry 48: 333–339

    PubMed  CAS  Google Scholar 

  • Hiemke C, Weigmann H, Härtter S, Dahmen N, Wetzel H, Müller H (1994) Elevated levels in serum of clozapine after addition of fluvoxamine. J Clin Psychopharmacol 14: 279–281

    PubMed  CAS  Google Scholar 

  • Hirsch S, Link CG, Goldstein JM, Arvanitis LA (1996) ICI 204,636. A new atypical antipsychotic drug. Br J Psychiatry i68(Suppl 29: 45–56

    Google Scholar 

  • Hoge SK, Appelbaum PS, Lawlor T, Beck JC, Litman R, Greer A, Gutheil TG, Kaplan E (1990) A prospective, multicenter study of patients’ refusal of antipsychotic medication. Arch Gen Psychiatry 47: 949–956

    PubMed  CAS  Google Scholar 

  • Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker WW (1999) Sexual disturbances during clozapine and haloperidol treatment for schizophrenia. Am J Psychiatry 156: 631–633

    PubMed  CAS  Google Scholar 

  • Janicak PG, Javaid JI, Sharma RP, Leach A, Dowd S, Davis JM (1997) A two-phase, double-blind randomized study of three haloperidol plasma levels for acute psychosis with reassignment of initial non-responders. Acta Psychiatr Scand 95: 343–350

    PubMed  CAS  Google Scholar 

  • Johnson DAW (1979) Further observations on the duration of depot neuroleptic maintenance therapy in schizophrenia. Br J Psychiatry 135: 524–530

    PubMed  CAS  Google Scholar 

  • Jolley AG, Hirsch SR, McRink A, Manchanda R (1989) Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical out-come at one year. BMJ 298: 985–990

    PubMed  CAS  Google Scholar 

  • Kammen DP van, McEvoy JP, Targum SD, Kardatzke D, Sebree T (1996) A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 124: 168–175

    PubMed  Google Scholar 

  • Kane JM, Lieberman JA (1987) Maintenance pharmacotherapy in schizophrenia. In: Meitzer HY (ed) Psychopharmacology the third generation of progress, Raven, New York, pp 1103–1109

    Google Scholar 

  • Kane J, Honigfeld G, Singer J, Meitzer HY (1988a) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789–796

    CAS  Google Scholar 

  • Kane JM, Woerner M, Lieberman J (1988b) Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 8(Suppl 4)152–56

    Google Scholar 

  • Kay SR (1991) Positive and negative syndromes in schizophrenia. Brunner/Mazel, New York

    Google Scholar 

  • Keck P Jr, Buffenstein A, Ferguson J et al. (1998) Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4–week placebo-controlled trial. Psychopharmacology 140: 173–184

    PubMed  CAS  Google Scholar 

  • Kemp R, Kirov G, Everitt B, Hayward P, David A (1998) Randomised controlled trial of compliance therapy. Br J Psychiatry 172: 413–419

    PubMed  CAS  Google Scholar 

  • Kinon BJ, Kane JM, Johns C, Perovich R, Ismi M, Koreen AR, Weiden PJ (1993) Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull 29: 309–314

    PubMed  CAS  Google Scholar 

  • Kissling W (1991) Duration of neuroleptic maintenance treatment. In: Kissling W (ed) Guidelines for neuroleptic relapse prevention in schizophrenia, Springer, Berlin Heidelberg New York Tokio, pp 94–112

    Google Scholar 

  • Kissling W, Kane JM, Barnes TRE, Dencker SJ, Fleischhacken WW, Goldstein JM, Johnson DAW, Marder SR, Müller-Spahn F, Tegeler J et al. (1991) Guidelines for neuroleptic relapse prevention in schizophrenia: towards a consensus view. In: Kissling W (ed) Guidelines for neuroleptic relapse prevention in schizophrenia, Springer, Berlin Heidelberg New York Tokio, pp 155–163

    Google Scholar 

  • Klieser E, Lehmann E, Tegeler J (1991) Double-blind comparison of 3x75 mg zotepine and 3x4 mg haloperidol in acute schizophrenic patients. Fortschr Neurol Psychiatr 59 (Suppl 1): 14–17

    PubMed  Google Scholar 

  • Kolakowska T, Williams AO, Ardern M, Reveley MA, Jambor K, Gelder MG, Mandelbrote BM (1985) Schizophrenia with good and poor outcome. I. Early clinical features, response to neuroleptics and signs of organic dysfunction. Br J Psychiatry 146: 229–239

    PubMed  CAS  Google Scholar 

  • Kraepelin E (1919) Dementia praecox and paraphrenia. Livingstone, Edinburgh

    Google Scholar 

  • Krueger RB, Sackeim HA (1995) Electroconvulsive therapy and schizophrenia. In: Hirsch SR, Weinberger DR (eds) Schizophrenia. Blackwell, Oxford, pp 503–545

    Google Scholar 

  • Kurz M, Hummer M, Oberbauer H, Fleischhacker WW (1995a) Extra-pyramidal side effects of clozapine and haloperidol. Psychopharmacology 118: 52–56

    CAS  Google Scholar 

  • Kurz M, Hummer M, Kurzthaler I, Oberbauer H, Fleischhacker WW (1995b) Efficacy of medium-dose clozapine for treatment resistant schizophrenia. Am J Psychiatry 152: 1690–1691

    CAS  Google Scholar 

  • Lehman AF, Steinwachs DM (1998) Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 24: 1–10

    PubMed  CAS  Google Scholar 

  • Lemmens P, Brecher M, Van Baelen B (1999) A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr Scand 99: 160–170

    PubMed  CAS  Google Scholar 

  • Levinson DF, Simpson GM, Singh H, Yadalam K, Jain A, Stephanos MJ, Silver P (1990) Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Arch Gen Psychiatry 47: 761–768

    PubMed  CAS  Google Scholar 

  • Levinson DF, Singh H, Simpson GM (1992) Timing of acute clinical response to fluphenazine. Br J Psychiatry 160: 365–371

    PubMed  CAS  Google Scholar 

  • Levinson DF, Simpson GM, Lo ES, Cooper TB, Singh H, Yadalam K, Stephanos MJ (1995) Fluphenazine plasma levels, dosage, efficacy, and side effects. Am J Psychiatry 152: 765–771

    PubMed  CAS  Google Scholar 

  • Ley P, Spelman MS (1965) Communication in an outpatient setting. Br J Soc Clin Psychology 4: 114–116

    CAS  Google Scholar 

  • Liddle PF, Barnes TRE, Curson DA, Patel M (1993) Depression and the experience of psychological deficits in schizophrenia. Acta Psychiatr Scand 88: 243–247

    PubMed  CAS  Google Scholar 

  • Loebel A, Lieberman J, Alvir J, Geisler J, Koreen A, Chakos M (1995) Time to treatment response in successive episodes of early onset schizophrenia (abstract). Schizophr Res 15: 158

    Google Scholar 

  • Loo H, Poirier-Littre MF, Theron M, Rein W, Fleurot O (1997) Amisulpride versus placebo in the med-ium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 170: 18–22

    PubMed  CAS  Google Scholar 

  • Madhusoodanan S, Brecher M, Brenner R, Kasckow J, Kunik M, Negron AE, Pomara N (1999) Risperidone in the treatment of elderly patients with psychotic disorders. Am J Geriatr Psychiatry 7: 132–138

    PubMed  CAS  Google Scholar 

  • Mandoki MW (1995) Risperidone treatment of children and adolescents: increased risk of extrapyramidal side effects? J Child Adolesc Psychopharmacol 5: 49–67

    Google Scholar 

  • Marder SR (1998) Facilitating compliance with antipsychotic medication. J Clin Psychiatry 59 (Suppl. 3)121–25

    Google Scholar 

  • Marder SR, Meibach RC (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151: 825–835

    PubMed  CAS  Google Scholar 

  • McEvoy JP, Hogarty GE, Steingard S (1991) Optimal dose of neuroleptics in acute schizophrenia. Arch Gen Psychiatry 48: 739–745

    PubMed  CAS  Google Scholar 

  • Meise U, Günther V, Gritsch S (1992) Die Bedeutung der Arzt-Patienten-Beziehung für die Patienten compliance. Wien Klin Wochenschr 104: 267–271

    PubMed  CAS  Google Scholar 

  • Meitzer HY (1989) Duration of a clozapine trial in neuroleptic-resistant schizophrenia. Arch Gen Psychiatry 46: 672

    Google Scholar 

  • Meitzer HY, Okayli G (1995) The reduction of suicidality during clozapine treatment in neuroleptic- resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 152: 183–190

    Google Scholar 

  • Meitzer HY, Burnett S, Bastani B, Ramirez LF (1990) Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 41: 892–897

    Google Scholar 

  • Middelboe T (1995) Predictors of treatment compliance in long- term mentally ill. Eur Neuropsychopharmacol 5: 318

    Google Scholar 

  • Miller CH, Fleischhacker WW (2000) Managing of antipsychotic induced acute and chronic akathisia. Drug Safety 22: 73–81

    PubMed  CAS  Google Scholar 

  • Miller DD, Fleming F, Holman TL, Perry PJ (1994) Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry 55 (Suppl 9B): 117–121

    PubMed  Google Scholar 

  • Mortimer A (1997) Cognitive function in schizophrenia do neuroleptics make a difference? Pharmacol Biochem Behav 56: 789–795

    PubMed  CAS  Google Scholar 

  • Möller HJ (1995) The negative component in schizophrenia. Acta Psychiatr Scand 91 (Suppl 388): 11–14

    Google Scholar 

  • Möller HJ, Zerssen D von (1995) Course and outcome of schizophrenia. In: Hirsch SR, Weinberger DR (eds) Schizophrenia, Blackwell, Oxford, pp 106–127

    Google Scholar 

  • Nordstrom A, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G (1995) D„ D2, and 5–HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 152: 1444–1449

    PubMed  CAS  Google Scholar 

  • Nyberg S, Farde L, Halldin C (1997) A PET study of 5–HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 16: 1–7

    PubMed  CAS  Google Scholar 

  • Overall JE (1972) The Brief Psychiatric Rating Scale in Psychopharmacology Research. University of Texas, Galvaston (Psychometric laboratory reports 29 )

    Google Scholar 

  • Paillere-Martinot ML, Lecrubier Y, Martinot JL, Aubin F (1995) Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 152: 130–134

    PubMed  CAS  Google Scholar 

  • Pan PC, Tantam D (1989) Clinical characteristics, health beliefs and compliance with maintenance treatment: a comparison between regular and irregular attenders at a depot clinic. Acta Psychiatr Scand 79: 564–570

    PubMed  CAS  Google Scholar 

  • Perlick D, Mattis S, Stastny P, Teresi J (1992) Neuropsychological discriminators of long-term inpatient or outpatient status in chronic schizophrenia. J Neuropsychiatr Clin Neurosci 4: 428–434

    CAS  Google Scholar 

  • Petit M, Raniwalla J, Tweed J, Leutenegger E, Dollfus S, Kelly F (1996) A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial. Psychopharmacol Bull 32: 81–87

    PubMed  CAS  Google Scholar 

  • Peuskens J (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-centre, double- blind, parallel-group study versus haloperidol. Br J Psychiatry 166: 712–726

    PubMed  CAS  Google Scholar 

  • Pfeiffer W, Kockott G, Fischi B, Schleuning G (1991) Unerwünschte Wirkungen psychopharmakologischer Langzeittherapie auf die sexuellen Funktionen. Psychiatr Prax 18: 92–98

    PubMed  CAS  Google Scholar 

  • Pietzcker A, Gaebel W, Kopeke W, Linden M, Müller P, Müller- Spahn F, Tegeler J (1993) Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia 2–year results of a German multicenter study. J Psychiatr Res 27: 321–339

    Google Scholar 

  • Pilowsky LS, O’Connell P, Davies N, Busatto GF, Costa DC, Murray PJ, Kerwin RW (1997) In vivo effects on striatal dopamine D2 receptor binding by the novel atypical antipsychotic drug sertindole - a 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology 130: 152–158

    PubMed  CAS  Google Scholar 

  • Potkin SG, Bera R, Gulasekaram B et al. (1994) Plasma clozapine concentrations predict clinical re¬sponse in treatment-resistant schizophrenia. J Clin Psychiatry 55 (Suppl 9B): 133–136

    PubMed  Google Scholar 

  • Prakash A, Lamb HM (1998) Zotepine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 9: 154–175

    Google Scholar 

  • Remington G, Bezchlibnyk-Butler K (1996) Management of acute antipsychotic-induced extrapyramidal syndromes. CNS Drugs 5 (Suppl 1): 21–35

    Google Scholar 

  • Rifkin A, Doddi S, Karagi B et al. (1991) Dosage of haloperidol for schizophrenia. Arch Gen Psychiatry 48: 166–170

    PubMed  CAS  Google Scholar 

  • Rosenheck R, Cramer J, Xu W et al. (1997) A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 337: 809–815

    PubMed  CAS  Google Scholar 

  • Roth BL, Meitzer HY (1995) The role of serotonin in schizophrenia. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress, Raven, New York, pp 1215–1227

    Google Scholar 

  • Rowley HL, Kilpatrick IC, Needham PL, Heal DJ (1998) Elevation of extracellular cortical noradrenaline may contribute to the antidepressant activity of zotepine: an in vivo microdialysis study in freely moving rats. Neuropharmacology 37: 937–944

    PubMed  CAS  Google Scholar 

  • Roy A (1986) Depression, attempted suicide, and suicide in patients with chronic schizophrenia. Psychiatr Clin North Am 9: 193–206

    PubMed  CAS  Google Scholar 

  • Sailer FC, Salama AI (1993) Seroquel: biochemical profile of a potential atypical antipsychotic. Psycho- pharmacology 112: 285–292

    Google Scholar 

  • Schmutz J, Hunziker F, Stille G, Lauener H (1967) Constitution chimique et action pharmacologique d’un nouveau groupe de neuroleptiques tricycliques. Bull Chim Therapeut: 424

    Google Scholar 

  • Schooler NR, Keith SJ, Severe JB et al. (1997) Relapse and hospitalization during maintenance treatment of schizophrenia: the effects of dose reduction and family treatment. Arch Gen Psychiatry 54: 453–463

    PubMed  CAS  Google Scholar 

  • Schou M (1997) The combat of noncompliance during prophylactic lithium treatment. Acta Psychiatr Scand 95: 361–363

    PubMed  CAS  Google Scholar 

  • Schulz SC, Kahn EM, Baker RW, Conley RR (1990) Lithium and Carbamazepin augmentation in treatment refractory schizophrenia. In: Angrist B, Schulz SC (eds) The neuroleptic nonresponsive patient: characterization and treatment, APA, Washington DC, pp 109–136

    Google Scholar 

  • Schultz SK, Miller DD, Arndt S, Ziebeli S, Gupta S, Andreasen NC (1995) Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic dis-continuation. Biol Psychiatry 38: 713–719

    PubMed  CAS  Google Scholar 

  • Schwartz D, Wang W, Zeitz L, Goss ME (1962) Medication errors made by elderly, chronically ill patients. Am J Public Health 52: 2018–2029

    CAS  Google Scholar 

  • Shalev A, Hermesh H, Rothberg J, Munitz H (1993) Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatr Scand 87: 86–91

    PubMed  CAS  Google Scholar 

  • Sharma T, Mockler D (1998) The cognitive efficacy of atypical antipsychotics in schizophrenia. J Clin Psychopharmacol 18 (Suppl 1): 12–19

    Google Scholar 

  • Shiloh R, Zemishlany Z, Aizenberg D et al. (1997) Sulpiride augmentation in people with schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled study. Br J Psychiatry 171: 569–573

    PubMed  CAS  Google Scholar 

  • Silver H, Kushnir M, Kaplan A (1996) Fluvoxamine augmentation in clozapine-resistant schizophrenia: an open pilot study. Biol Psychiatry 40: 671–674

    PubMed  CAS  Google Scholar 

  • Silverstone T, Smith G, Goodall E (1988) Prevalence of obesity in patients receiving depot antipsychotics. Br J Psychiatry 153:214– 217

    Google Scholar 

  • Siris SG (1995) Depression and schizophrenia. In: Hirsch SR, Weinberger DR (eds) Schizophrenia, Blackwell, Oxford, pp 128–145

    Google Scholar 

  • Skarsfeldt T (1995) Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 281: 289–294

    PubMed  CAS  Google Scholar 

  • Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CGG (1997) Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 54: 549–557

    PubMed  CAS  Google Scholar 

  • Smith JM (1980) Abuse of antiparkinsonian drugs a review of the literature. J Clin Psychiatry 41: 351–354

    PubMed  CAS  Google Scholar 

  • Steingard S, Allen M, Schooler NR (1994) A study of the pharmacologic treatment of medication- compliant schizophrenics who relapse. J Clin Psychiatry 55: 470–472

    PubMed  CAS  Google Scholar 

  • Sternlicht HC, Wells SR (1995) Ris-peridone in childhood schizophrenia. J Am Acad Child Adolesc Psychiatry 34: 540

    PubMed  CAS  Google Scholar 

  • Stille G, Hippius H (1971) Kritische Stellungnahme zum Begriff der Neuroleptika. Pharmakopsychiatr Neuropharmakol 4: 182–191

    CAS  Google Scholar 

  • Swett C Jr, Noones J (1989) Factors associated with premature termination from outpatient treatment. Hosp Community Psychiatry 40: 947–951

    PubMed  Google Scholar 

  • Tandon R, Mann NA, Eisner WH, Coppard N (1990) Effect of anti-cholinergic medication on positive and negative symptoms in medication-free schizophrenic patients. Psychiatry Res 31: 235–241

    PubMed  CAS  Google Scholar 

  • Tandon R, Harrigan E, Zorn SH (1997) Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential. J Serotonin Res 4: 159–177

    Google Scholar 

  • Tollefson GD, Sanger TM, Beasley CM (1997) Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 154: 466–474

    PubMed  CAS  Google Scholar 

  • Tollefson GD, Beasley CM Jr, Tran PV et al. (1997a) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154: 457–465

    CAS  Google Scholar 

  • Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH (1997b) Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 154: 1248–1254

    CAS  Google Scholar 

  • Tollefson GD, Sanger TM, Lu Y, Thieme ME (1998) Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 55:250– 258

    Google Scholar 

  • Tran PV, Dellva MA, Tollefson GD, Beasley CM Jr, Potvin JH, Kiesler GM (1997) Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 58: 205–211

    PubMed  CAS  Google Scholar 

  • Tran PV, Dellva MA, Tollefson GD, Wentley AL, Beasley CM Jr (1998) Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry 172: 499–505

    PubMed  CAS  Google Scholar 

  • Travis MJ, Busatto GF, Pilowsky LS et al. (1998) 5HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine: a SPET study using the novel 5HT2A ligand123I-5I-R-91150. Br J Psychiatry 173:236–241

    Google Scholar 

  • VanderZwaag C, McGee M, McEvoy JP, Freudenreich O, Wilson WH, Cooper TB (1996) Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 153: 1579–1584

    PubMed  CAS  Google Scholar 

  • Van Putten T (1974) Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 31: 67–72

    PubMed  Google Scholar 

  • Van Putten T, May PRA, Marder SR (1984) Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry 41: 1036–1039

    PubMed  Google Scholar 

  • Van Putten T, Marder SR, Mintz J, Poland RE (1992) Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry 149: 500–505

    PubMed  Google Scholar 

  • Volavka J, Cooper T, Czobor P et al. (1992) Haloperidol blood levels and clinical effects. Arch Gen Psychiatry 49: 354–361

    PubMed  CAS  Google Scholar 

  • Weiss E, Danzi C, Hummer M, Kemmler G, Lindner C, Reinstadler K, Fleischhacker WW (1998) Weight gain induced by olanzapine. Schizophr Res 29 (Special issue 1/2): 179

    Google Scholar 

  • Wetzel H, Gründer G, Hillert A et al. (1998) Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology a double-blind controlled study comparing a selective D2–like antagonist to mixed D1-/D2–like antagonist. Psycho- pharmacology 135: 223–232

    Google Scholar 

  • Whitworth AB, Fleischhacker WW (1995) Adverse effects of antipsychotic drugs. Int Clin Psychopharmacol 9 (Suppl 5): 21–27

    PubMed  Google Scholar 

  • WHO (1990) Prophylactic use of anticholinergics in patients on long- term neuroleptic treatment. Br J Psychiatry 156: 412–414

    Google Scholar 

  • Willcox DR, Gillan R, Hare EH (1965) Do psychiatric out-patients take their drugs? Br Med J 5465:790– 792

    Google Scholar 

  • Wilson WH (1993) Addition of lithium to haloperidol in non-affective, antipsychotic nonresponsive schizophrenia: a double

    Google Scholar 

  • blind, placebo controlled, parallel design clinical trial. Psychopharmacology 111:359–366

    Google Scholar 

  • Wirshing WC, Marder SR, Van Putten T, Ames D (1995) Acute treatment of schizophrenia. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology the fourth generation of progress, Raven Press, New York, pp 1259–1266

    Google Scholar 

  • Wolkowitz OM, Rapoport MH, Pickar D (1990) Benzodiazepine augmentation of neuroleptics. In: Angrist B, Schulz SC (eds) The neuroleptic nonresponsive patient: characterization and treatment. APA, Washington DC, pp 87–108

    Google Scholar 

  • Wyatt R (1991) Neuroleptics and the natural course of schizophrenia. Schizophr Bull 17: 325–351

    PubMed  CAS  Google Scholar 

  • Zimbroff DL, Kane JM, Tamminga CA et al. (1997) Controlled, dose response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 154: 782–791

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. W. W. Fleischhacker
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische Klinik, Freie Universität Berlin, Eschenallee 3, D-14050, Berlin, Germany

    Hanfried Helmchen

  2. Klinikum rechts der Isar, Technische Universität Müchen, Ismaninger Str. 22, D-81675, München, Germany

    Hans Lauter

  3. Zentralinstitut für Seelische Gesundheit, Postfach 12 21 20, D-68072, Mannheim, Germany

    Fritz Henn

  4. Hôpitaux Universitaires de Genève, Belle-Idée, Bâtiment Salève 2, chemin du Petit-Bel-Air, CH-1225, Chêne-Bourg/Genève, Switzerland

    Norman Sartorius

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Fleischhacker, W.W. (2000). Pharmakotherapie schizophrener Störungen. In: Helmchen, H., Lauter, H., Henn, F., Sartorius, N. (eds) Psychiatrie der Gegenwart 5. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59626-1_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-59626-1_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64057-5

  • Online ISBN: 978-3-642-59626-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation